News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023

Published:2023-09-25 Issue:1 Volume:18 Page:
ISSN:1750-1326
Container-title:Molecular Neurodegeneration
language:en
Short-container-title:Mol Neurodegeneration

Author:

Gandy Sam^ORCID

Funder

National Institute on Aging

Cure Alzheimer's Fund

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology (clinical),Molecular Biology

Link

https://link.springer.com/content/pdf/10.1186/s13024-023-00656-x.pdf

Reference12 articles.

1. Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020;15(1):40. https://doi.org/10.1186/s13024-020-00391-7.PMID:32677986;PMCID:PMC7364557.

2. Gandy S, Knopman DS, Sano M. Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA. Mol Neurodegener. 2021;16(1):74. https://doi.org/10.1186/s13024-021-00490-z.PMID:34736482;PMCID:PMC8569969.

3. Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert Opin Investig Drugs. 2023;32(2):89–94. https://doi.org/10.1080/13543784.2023.2178414.PMID:36749830;PMCID:PMC10275297.

4. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9–21. https://doi.org/10.1056/NEJMoa2212948. PMID: 36449413.

5. Cynis H, Frost JL, Crehan H, Lemere CA. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges. Mol Neurodegener. 2016;11(1):48. https://doi.org/10.1186/s13024-016-0115-2.PMID:27363697;PMCID:PMC4929720.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-08

2. A Strategy for Allowing Earlier Diagnosis and Rigorous Evaluation of BACE1 Inhibitors in Preclinical Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-05-14

3. Brain morphology mediating the effect of genetic risk variants on Alzheimer’s disease;2024-01-13

4. Irisin limits amyloid-β buildup in Alzheimer’s disease;Trends in Endocrinology & Metabolism;2023-12

5. Loss of TREM2 exacerbates parenchymal amyloid pathology but diminishes CAA in Tg-SwDI mice;2023-11-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3